1,080 Shares in United Therapeutics Corporation $UTHR Acquired by PSP Research LLC

PSP Research LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,080 shares of the biotechnology company’s stock, valued at approximately $526,000.

A number of other large investors have also bought and sold shares of UTHR. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $317,617,000. Baillie Gifford & Co. acquired a new stake in United Therapeutics during the 4th quarter worth $157,390,000. Balyasny Asset Management L.P. raised its stake in United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after buying an additional 136,883 shares during the period. Sofinnova Investments Inc. acquired a new stake in United Therapeutics during the 2nd quarter worth $34,055,000. Finally, Orbimed Advisors LLC acquired a new stake in United Therapeutics during the 3rd quarter worth $48,167,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Michael Benkowitz sold 14,440 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 550,413 shares of company stock valued at $305,867,937 in the last 90 days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $566.80 on Wednesday. The stock has a market capitalization of $24.06 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 1.83 and a beta of 0.60. The business has a 50-day moving average of $561.48 and a 200-day moving average of $509.54. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.63 EPS. On average, sell-side analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on UTHR shares. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Finally, Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.